Codexis Inc CDXS Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Ryali Sriram

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,125

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Ryali Sriram

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

52,350

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Norrett Kevin

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,125

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Norrett Kevin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

52,350

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Fitzgerald Margaret Nell

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,125

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Fitzgerald Margaret Nell

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

52,350

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Dilly Stephen George

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

860,500

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Dilly Stephen George

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

143,425

Price:

--
Nov 15, 2023 (filed on Nov 17, 2023)

Insider Name:

Dorgan Byron L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-20,000

Price:

$2.11
Nov 09, 2023 (filed on Nov 14, 2023)

Insider Name:

Singhvi Rahul

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--

Filings by filing date

Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Ryali Sriram

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,125

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Ryali Sriram

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

52,350

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Norrett Kevin

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,125

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Norrett Kevin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

52,350

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Fitzgerald Margaret Nell

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

314,125

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Fitzgerald Margaret Nell

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

52,350

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Dilly Stephen George

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

860,500

Price:

--
Jan 01, 2024 (filed on Jan 02, 2024)

Insider Name:

Dilly Stephen George

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

143,425

Price:

--
Nov 15, 2023 (filed on Nov 17, 2023)

Insider Name:

Dorgan Byron L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-20,000

Price:

$2.11
Nov 09, 2023 (filed on Nov 14, 2023)

Insider Name:

Singhvi Rahul

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

10,000

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	200 Penobscot Dr REDWOOD CITY CA 94063-4718
Tel:	1-650-4218399
Website:	https://www.codexis.com
IR:	See website

Key People

Stephen G. Dilly President, Chief Executive Officer, Director	Sriram Ryali Chief Financial Officer, Chief Accounting Officer	Kevin Norrett Chief Operating Officer
Margaret Nell Fitzgerald Chief Legal and Compliance Officer, General Counsel and Secretary

Business Overview

Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.

Financial Overview

For the fiscal year ended 31 December 2023, Codexis Inc revenues decreased 49% to $70.1M. Net loss increased from $33.6M to $76.2M. Revenues reflect EMEA segment decrease of 59% to $22.9M, APAC segment decrease of 48% to $33.5M. Higher net loss reflects Other expenses net, decrease from $124K (income) to $12.3M (expense), Selling and General Expenses increase of 10% to $46M (expense).

Employees:	174 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$138.76M as of Dec 31, 2023
Annual revenue (TTM):	$70.14M as of Dec 31, 2023
EBITDA (TTM):	-$49.28M as of Dec 31, 2023
Net annual income (TTM):	-$76.24M as of Dec 31, 2023
Free cash flow (TTM):	-$57.06M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	70,303,639 as of Feb 23, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization